In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide
about
Low-level vancomycin resistance in Clostridium innocuum.LeprosyEffect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complexComparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycinIn vitro and in vivo activities of clarithromycin against Mycobacterium aviumIn vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondiiEffect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin.Penetration of clarithromycin into lung tissues from patients undergoing lung resectionEffect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents.Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections.Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia.Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin.Antibacterial activity of RU 64004 (HMR 3004), a novel ketolide derivative active against respiratory pathogensIn vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycinClarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles.In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycinSusceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model.In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.In vitro and in vivo activities of macrolides against Mycobacterium lepraeActivities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organismsClarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS.In vitro activity and in vivo efficacy of a new series of 9-deoxo-12-deoxy-9,12-epoxyerythromycin A derivatives.Variability of clarithromycin and erythromycin susceptibility tests with Haemophilus influenzae in four different broth media and correlation with the standard disk diffusion test.Regression analysis, proposed interpretative zone size standards, and quality control guidelines for a new macrolide antimicrobial agent, A-56268 (TE-031).Long-term and per rectum disposition of Clarithromycin in the desert tortoise (Gopherus agassizii).Modeling the autoinhibition of clarithromycin metabolism during repeated oral administrationFundamental functionality: recent developments in understanding the structure-activity relationships of lantibiotic peptides.In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae.Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.New directions for macrolide antibiotics: structural modifications and in vitro activity.New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy.Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniaeSimplified quantitative assay system for measuring activities of drugs against intracellular Legionella pneumophila.Autobacteriographic studies of clarithromycin and erythromycin in mice.Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system.Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice.In vitro activity of YM133, a new semisynthesized macrolide.
P2860
Q24517838-6866DDB2-1D6A-4E24-8822-809C5BE87515Q24617200-870AAE89-FE65-4223-A494-954A661E4F0FQ28326618-EE1E362C-5878-4CF6-A6A1-F4274B6CFDF6Q28341927-F608C894-3722-4109-8DB8-F940D579552EQ28342095-8A77F273-DA2C-470A-B56C-3D70CD6E2AFAQ28359823-71E1F237-D1D6-4F47-85FA-536FDFBAD2B8Q33748441-581099C6-6F04-49B5-89E9-97CF8B1A16B2Q33753604-854C2FDB-F3EE-4449-99C1-AD8D80760FC9Q33977311-59BB6D6A-784F-43FD-9EEB-CE3F848F4452Q34303042-BB49B69E-2442-4AB3-8A17-A9F060DCD644Q34938903-0FCAF898-51D1-4A4E-9C15-28F37DADD08BQ35111440-1AAEE2E7-1D20-4CC6-B420-A7A983FAA320Q35138464-67C31D39-5183-4F20-B995-21B7C89C3E5BQ35305599-D37932AA-824B-4A8E-A27B-629E90717386Q35466622-FDD887CE-2417-4597-B02E-A49CCAB55DDBQ35537259-1D96B843-2A36-43D4-9645-159133017F5DQ35541132-E43719AD-B1D2-4F2A-9D76-4CDF2FF82432Q35564364-7A9AD2C9-A072-4FAA-BB33-050137679E58Q35564733-D16B1F17-078C-46EB-92F5-DEE1583D08BBQ35565331-300EF9BB-7800-44B9-BF1C-C45475B5694BQ35565659-9CF21D41-8488-4581-B88C-44DDB2630C13Q35843595-FA59C861-A3B4-496B-90B3-BC53A6B7326DQ35885553-91344490-1D58-4F93-92C7-C41FEEC5CDD1Q36753797-BFC8F35C-1CB0-4A02-8199-F4BFD9A22D44Q37158402-4BC01A7A-E1A5-4494-B978-523025D56550Q37214432-5367225E-7536-4760-B79D-BDA42B1526E8Q37223359-EECFA848-6932-4F9D-AF39-A97A6A2055CDQ37247655-B0B6F4A0-A94F-4705-A1E9-F04915FF081DQ37809967-C82F37F6-3FD3-4C16-8345-1E9EFE68391AQ37884244-FD9C58C3-2449-41F1-BE88-287E7A6F0EFAQ37900922-844305FA-9393-4AE1-9AB5-9B3C6053F5E5Q38100704-EC4FA4A6-89E5-4163-A7C6-0F5A0C7E0BF2Q38721368-70DF879C-64C4-41F5-825E-E399548E6B80Q38721378-9CBAD6E4-733E-4D6D-8EF1-E33DDBC9EA1BQ39470774-EA9EF8DD-894A-4EAA-B67F-C1C6AD1EB2D2Q39553788-756B39D9-9CA0-45E0-A5CA-F3EF4ACE6A9DQ39815656-A9971931-C938-4A99-AA05-B7D4E51D3607Q39881867-5A0A03B7-1261-49E3-B791-ACCEEBFBE6D6Q40086380-4D2943B1-D844-4614-8CE0-1789202F3338Q40086793-5E252E10-4722-4C6F-BA22-4CD272CA8460
P2860
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
1986年论文
@zh
1986年论文
@zh-cn
name
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide
@ast
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide
@en
type
label
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide
@ast
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide
@en
prefLabel
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide
@ast
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide
@en
P2093
P2860
P356
P1476
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide
@en
P2093
Fernandes PB
McDonald E
Shipkowitz N
P2860
P304
P356
10.1128/AAC.30.6.865
P407
P577
1986-12-01T00:00:00Z